Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-04-26 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
SELUMETINIB RECOMMENDED FOR EU APPROVAL IN NF1
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains a detailed announcement about the recommendation for EU approval of the drug Selumetinib for a specific medical condition, including clinical trial results and regulatory designations. The document does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is primarily a regulatory announcement about a product approval and clinical trial results. Form 6-K filings are generally considered Regulatory Filings (RNS) as they provide material information but are not full financial reports or other specific filings like earnings releases or management reports. The document length (10,474 characters) and content confirm it is a substantive regulatory announcement rather than a brief notice or a full financial report.
2021-04-26 English
Selumetinib recommended for EU approval in NF1
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 5117W' and is dated April 26, 2021. It announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the recommendation for marketing authorisation of a drug (Selumetinib) in the EU. The text is a formal press release style announcement containing clinical trial results and company commentary. Crucially, it is distributed via RNS, the news service of the London Stock Exchange, and contains standard RNS footer information. This type of announcement, which is a formal regulatory disclosure but not a comprehensive financial report (like 10-K or IR) or a specific corporate action notice (like DIV or SHA), fits best under the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous regulatory announcements not covered by more specific codes. Given the context of a major regulatory milestone announcement distributed through the official exchange mechanism, RNS is the most appropriate classification.
2021-04-26 English
Tagrisso adjuvant receives positive CHMP opinion
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number' and is dated April 26, 2021. It announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the marketing authorisation of Tagrisso in the EU, based on Phase III trial results. This is a specific, time-sensitive announcement of a regulatory/clinical development milestone, not a comprehensive annual report (10-K), an interim report (IR), or a general earnings release (ER). Since it is a formal announcement distributed via the RNS system, and it details a specific regulatory event (CHMP recommendation), it fits best under the general 'Regulatory Filings' category (RNS) as a significant, non-standard announcement, although it is highly specific. Given the options, RNS serves as the best fit for a general regulatory news release that isn't a standard financial report or a specific insider/dividend announcement.
2021-04-26 English
Nirsevimab Phase III trial met primary endpoint
Regulatory Filings Classification · 98% confidence The document is an official announcement released via RNS (RNS Number : 5125W) on April 26, 2021, by AstraZeneca PLC. It details the positive results of the MELODY Phase III trial for the drug Nirsevimab concerning RSV infections in infants. This type of announcement, which communicates significant clinical trial results and corporate/product updates through a regulatory news service, fits best under the general 'Regulatory Filings' category (RNS) as it is not a full Annual Report (10-K), a specific Earnings Release (ER) focusing only on financials, or a dedicated Investor Presentation (IP). While it contains scientific information, its primary function here is a regulatory disclosure of a material event via the RNS system.
2021-04-26 English
US CLEARANCE OF PROPOSED ACQUISITION OF ALEXION
M&A Activity Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the announcement of US clearance of the proposed acquisition of Alexion Pharmaceuticals, including regulatory updates, forward-looking statements, and details about the acquisition process. It is not a full annual or quarterly report, audit report, or earnings release. It is also not a proxy solicitation or voting results announcement, but rather an update on a capital transaction (acquisition) and regulatory clearances related to it. The document is lengthy (15,000 characters) and contains substantive information about the acquisition progress and regulatory status, which fits the category of M&A Activity announcements. Therefore, the appropriate classification is M&A Activity (TAR).
2021-04-16 English
US clearance of proposed acquisition of Alexion
M&A Activity Classification · 99% confidence The document is an official announcement dated April 16, 2021, originating from AstraZeneca PLC and distributed via RNS (RNS Number : 7566V). The core content discusses the achievement of US Federal Trade Commission clearance for the proposed acquisition of Alexion Pharmaceuticals, Inc. This is a significant corporate action related to a merger/takeover. The document explicitly mentions the acquisition was first announced in December 2020 and discusses regulatory clearances, shareholder voting anticipation, and the creation of a new business unit post-close. This clearly falls under the category of M&A Activity (TAR). It is not a general regulatory filing (RNS) because it concerns a specific, major corporate transaction (M&A), nor is it a proxy statement (DEF 14A) or an earnings release (ER).
2021-04-16 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.